SPH 3127

Drug Profile

SPH 3127

Alternative Names: SPH3127

Latest Information Update: 18 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Mitsubishi Tanabe Pharma Corporation; Shanghai Pharmaceuticals Holding
  • Developer Shanghai Pharmaceuticals Holding
  • Class Antihypertensives
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Hypertension

Most Recent Events

  • 18 Aug 2017 Shanghai Pharmaceuticals plans a phase I trial for Hypertension (In volunteers) (NCT03249753)
  • 24 Apr 2017 Phase-I clinical trials in Hypertension (In volunteers) in China (PO) (NCT03128138)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top